The Hotbox Q&A: 5 Questions with James Wilder Sr.
Your story is powerful. You’re a veteran, a father to five kids, three living with Sickle Cell, and the founder of your own firm. How have those life experiences shaped your approach to business, leadership, and the way you help clients?
Everything I do comes back to survival and service. The Marines taught me discipline and accountability. You fight for your team, you carry your weight, and you do not leave people behind. Fatherhood has taught me patience and faith. Having three children with Sickle Cell taught me what real endurance looks like. It has been tough, but you just have to keep fighting to survive.
I live every day knowing that access matters. Access to care, access to research, access to options. That reality changes how you see everything. I do not look at a tax return and see numbers. I see people trying to stay afloat in systems that were not designed with them in mind.
So, when I build strategies, I am not chasing clever ideas you see on Facebook or X. I am protecting stability. I am building systems that can hold up under pressure, because when businesses survive, families survive. That mindset shapes every decision I make.
Your firm is built on a “Make It Make Sense” philosophy, turning complicated tax code into something real and accessible. What does that look like in practice, especially for small businesses and cannabis operators trying to stay compliant under 280E?
In practice, it means translating IRS language into decisions people can actually use. Cannabis operators are playing the game with a handicap. Section 280E taxes them on income they never really take home, so precision matters.
That starts with structure, but structure alone is not enough. Accurate accrual accounting is critical. Inventory does not live in a cash world, and under Section 471, dispensaries still have to account for inventory correctly. If your books are sloppy, your COGS is weak, and if your COGS is weak, you are paying tax on money you never earned.
So, I focus on clean accrual accounting systems, defensible inventory accounting, and disciplined cost allocation. I help clients document every dollar, understand what truly belongs in COGS under the law, and keep non-inventory expenses where they belong. There are no shortcuts in the process. There is only clarity and consistency.
“Make It Make Sense” means building something stable enough to survive audits now and flexible enough to scale later. That stability is what allows businesses to reinvest in better operations, safer products, and research partnerships that actually move medicine forward.
You hold a Master of Cannabis Certification and specialize in 280E tax recovery. What are some of the biggest misconceptions people still have about 280E, and what should cannabis operators be doing right now to protect themselves financially?
Great questions, and this is huge and very important. The biggest misconception is that there is a loophole to escape 280E. There is not. There is only strategy, discipline, and documentation.
You cannot deduct ordinary business expenses, but you can properly calculate COGS. Most operators lose money not because 280E exists, but because their accounting does not hold up. Cash-basis books, missing inventory counts, poor accrual practices, and aggressive allocations are what get people in trouble. Compliance is not a burden. It is a weapon. Clean books, accurate accrual accounting, and defensible Section 471 inventory methodology are what keep the IRS off your back.
With all the talk around Schedule III, I am seeing operators assume relief is already here. It is not. Headlines are not law. Until rescheduling is finalized and implemented, 280E is still enforced today. The smart move is to stay disciplined now, so you are positioned to win later, regardless how the rules change.
You’ve seen both the human and financial toll of a broken system – from healthcare to taxation to federal policy. What’s your perspective on the political barriers that hold back progress for both cannabis reform and the families affected by conditions like Sickle Cell?
It comes down to visibility and voice. Sickle Cell does not receive the funding it deserves because it does not have the spotlight. Cannabis reform stalls because it lacks federal alignment. Both are life-and-death issues, yet they get treated like political chess pieces.
At the same time, in my personal experience, the doctors and researchers fighting for Sickle Cell patients are the heroes. The breakthroughs we are seeing today, gene therapy, improved treatments, and better outcomes exist because people refuse to stop pushing.
The issue is funding. Research depends on capital, and capital depends on industries that are allowed to survive. When Section 280E crushes cannabis businesses, it does not just hurt owners; it hurts families as well. It slows research and limits patient options.
I am hopeful about the direction things are moving, but hope alone does not keep doors open. That is why I fight where I can, keeping small businesses alive so they can help fund the breakthroughs that save lives, including my children’s.